Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Aug;50(2):186-9.
doi: 10.1097/00007890-199008000-00002.

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy

N Murase  1 , D G Kim, S Todo, D V Cramer, J J Fung, T E Starzl
Affiliations

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy

N Murase et al. Transplantation. 1990 Aug.

Abstract

Heterotopic heart and orthotopic liver grafts from ACI donors were transplanted to Lewis rat recipients that were treated with a 3 (or 4) day course of FK506 IM that was started on postoperative day 0, 2, 3, 4, 5, or 6. Hearts, which rejected after a median of 6 days in untreated controls, always had prolonged survival (median 91 days) when treatment was started on postoperative day 4. The results were inferior when treatment was started earlier or later than this, but even when the first dose of FK506 was on postoperative day 5, one day before rejection was imminent in controls, the median survival was 50 days. The poorest results with a median graft survival of only 36 days were obtained when injections were on days 0-3. Results were similar with liver grafts that rejected after a median time of 10 days in nontreated controls but that usually survived permanently after a 3 (or 4) day FK506 course starting on day 0, 2, 3, or 4. Therapy started on day 6 was too late.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
A. Untreated heart graft at day 5 showing mononuclear infiltration and interstitial edema of the myocardium. B. FK506-treated heart graft at day 5; i.m. FK506 was started on day 4; note mild scattered mononuclear infiltration. C. Untreated liver graft at day 7 with intense mononuclear cell infiltration of portal tracts and sinusoids with liver cell necrosis. D. FK506-treated liver graft at day 7; i.m. FK506 was given on days 4, 5, and 6. Although there are mononuclear cells in the portal tracts with slightly scattered cells through the sinusoids, the recipient had permanent acceptance of the graft.
See this image and copyright information in PMC

References

    1. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a streptomyces: I. Fermentation, isolation, and physio-chemical and biological characteristics. J Antibiot. 1987;60:1249. - PubMed
    1. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a streptomyces: II. Immunosuppressive effect of FK-506. J Antiboit. 1987;40:1256. - PubMed
    1. Ochiai T, Nakajima K, Nagata M. Effect of a new immunosuppressive agent, FK-506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc. 1987;19:1284. - PubMed
    1. Lee P, Murase N, Todo S, Makowka L, Starzl T. The immunosuppressive effects of FR 900506 in rats receiving heterotopic cardiac allografts. Surg Res Commun. 1987;1:325. - PMC - PubMed
    1. Murase N, Todo S, Lee PH, et al. Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc. 1987;19 suppl 6:71. - PMC - PubMed

Publication types

MeSH terms